A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon) on Glucose Control in Patients With Type I Diabetes
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2016
At a glance
- Drugs Exenatide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 20 Apr 2016 Planned End Date changed from 1 Sep 2016 to 1 Apr 2018.
- 20 Apr 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2017.